Fexofenadine

Introduction Overview

Generic Name

fexofenadine

Brand Name

Allegra 12 Hour Allergy, Allegra 24 Hour Allergy, Allegra Allergy, Allegra OTC, Aller-Ease, Allergy Relief (Fexofenadine HCl), Children's Allegra Allergy, Children's Allegra ODT

Dosage Form

oral suspension, oral tablet, oral disintegrating tablet

Drug Class

Antihistamines

Pharmacokinetics

Absorption:
Fexofenadine is administered orally, and its absorption occurs primarily in the gastrointestinal tract. Peak plasma concentration (Cmax) is typically reached within 1 to 3 hours after administration. The oral bioavailability of fexofenadine is approximately 30 to 40%, which is relatively low due to poor gastrointestinal permeability and active efflux by intestinal transporters such as P-glycoprotein (P-gp) and organic anion transporting polypeptides (OATPs). The absorption can be significantly impaired when co-administered with fruit juices (e.g., apple, orange, grapefruit), which inhibit these transporters and reduce plasma levels and clinical efficacy.

Distribution:
Fexofenadine exhibits a moderate volume of distribution, approximately 2.4 to 5.4 L/kg, indicating distribution into extracellular fluids but limited penetration into the central nervous system. Plasma protein binding ranges from 60 to 70%, primarily to albumin. Importantly, fexofenadine does not readily cross the blood-brain barrier, which accounts for its minimal sedative properties compared to first-generation antihistamines. The distribution is consistent with its action at peripheral H1 histamine receptors.

Metabolism:
Fexofenadine undergoes minimal hepatic metabolism, which distinguishes it from many other antihistamines extensively metabolized by cytochrome P450 enzymes. This limited metabolism reduces the potential for drug-drug interactions mediated through hepatic enzymes and contributes to its favorable safety profile. It remains largely unmetabolized and reaches systemic circulation in its active form after oral administration.

Elimination:
The primary route of elimination for fexofenadine is renal excretion of unchanged drug, accounting for approximately 70-80% of the administered dose. The elimination half-life ranges from 14 to 15 hours in healthy adults. The drug is excreted via both glomerular filtration and active tubular secretion. In patients with renal impairment, clearance is reduced, and dosage adjustments may be necessary. Fecal elimination accounts for a smaller fraction of the administered dose. The pharmacokinetic profile allows for once or twice daily dosing regimens depending on the formulation.

Dosage Forms

Available Dosage Forms:
- Oral tablet: 30 mg, 60 mg, 120 mg, 180 mg, 220 mg, and 240 mg strengths (depending on specific product)
- Oral disintegrating tablets (ODT): commonly 30 mg and 60 mg strengths
- Oral suspension (liquid): concentrations such as 30 mg/5 mL and 30 mg/10 mL available for pediatric use

Dosages for Adults and Adolescents:
- For seasonal allergic rhinitis: Adults and children 12 years and older are typically prescribed 60 mg twice daily or 180 mg once daily depending on the formulation.
- For chronic idiopathic urticaria: Adults and children 12 years and older generally receive 60 mg twice daily or 180 mg once daily.
- Children 6 to 11 years can use oral suspension with dose adjusted by weight and age, often 30 mg twice daily.
- Dosage forms like disintegrating tablets are recommended for children aged 6 years and older.

Specific Patient Populations:
- Pediatric: The oral suspension or lower dose tablets/disintegrating tablets are preferred for children aged 6 years and above.
- Geriatric: No specific dosing adjustment recommended, but sensitivity may be increased; monitoring is advised.
- Renal impairment: Dose adjustment is recommended in patients with impaired kidney function due to decreased clearance.
- Not typically used in children under 6 years (oral suspension dosage should be carefully considered).

Additional Clinical Guidelines:
- Take the oral disintegrating tablet on an empty stomach.
- Administer all forms with water; avoid fruit juices shortly before or after dosing as they reduce absorption.
- Shake oral suspension well before use and use provided measuring device for accurate dosing.

Mechanism Of Action

Fexofenadine is a selective peripheral H1 histamine receptor antagonist. Histamine, released from mast cells and basophils during allergic reactions, binds to H1 receptors causing symptoms such as vasodilation, increased vascular permeability, and sensory nerve stimulation resulting in itching, swelling, and sneezing. By competitively binding to H1 receptors on peripheral tissues, fexofenadine blocks the action of histamine, thereby inhibiting these hallmark allergy symptoms.

At the molecular level, fexofenadine exhibits high affinity for the H1 receptor without eliciting receptor activation, acting as a neutral antagonist. It does not cross the blood-brain barrier effectively, which limits its action in the central nervous system and accounts for its minimal sedative properties. This contrasts with first-generation antihistamines, which readily cross into the CNS and often cause drowsiness.

Fexofenadine acts on downstream signaling pathways by preventing histamine-induced activation of phospholipase C, phosphoinositide hydrolysis, and calcium mobilization. This blockade reduces vasodilation, vascular permeability, and sensory nerve depolarization that trigger allergic manifestations such as rhinorrhea, conjunctival injection, and pruritus.

Clinical studies have demonstrated that fexofenadine effectively reduces seasonal and perennial allergic rhinitis symptoms as well as chronic urticaria. Its selective action with minimal CNS penetration contributes to a favorable safety and tolerability profile, distinguishing it from sedating antihistamines. Comparative research against similar second-generation agents such as loratadine and cetirizine shows similar efficacy but with differences in half-life and dosing frequency.

Pharmacological Actions

Selective peripheral H1 histamine receptor antagonist action
Competitive inhibition of histamine binding at H1 receptors on target tissues
Reduction of histamine-mediated vasodilation and increased vascular permeability
Inhibition of histamine-induced sensory nerve activation responsible for itching and sneezing
Minimal penetration of the blood-brain barrier, leading to non-sedating antihistamine effects
Rapid onset of action with sustained activity for 12 to 24 hours depending on formulation
Effective anti-allergic activity in allergic rhinitis and chronic idiopathic urticaria
Low potential for anticholinergic or adrenergic side effects compared to first-generation agents
Absence of significant hepatic metabolism reduces drug-drug interaction potential
Excretion primarily via renal elimination of unchanged drug
Demonstrated safety and tolerability in both adult and pediatric populations
No known immunosuppressive or corticosteroid-like effects
Limited impact on cardiac conduction system; minimal QT prolongation risk
Non-addictive with no known abuse potential
Compatible with long-term daily use for chronic allergic conditions

Therapeutic Or Clinical Uses

Treatment and relief of symptoms associated with seasonal allergic rhinitis (hay fever) in adults and children
Management of perennial allergic rhinitis symptoms
Treatment of chronic idiopathic urticaria (hives) to reduce itching and frequency of wheals
Relief of other allergic skin manifestations characterized by histamine-mediated pruritus
Adjunct therapy in allergic conditions requiring symptom control without sedation
Alternative to first-generation sedating antihistamines for patients requiring daytime symptom relief
Used in pediatric patients aged 6 years and older for allergy symptom management
Symptomatic relief of nasal congestion, sneezing, rhinorrhea, and itchy/watery eyes related to allergies
Off-label use in some patients for relief of allergic conjunctivitis symptoms
Useful in patients sensitive to sedative effects of conventional antihistamines
Employed in treatment regimens for individuals with multiple allergies as maintenance therapy
Considered safe for long-term use in chronic allergic conditions with minimal adverse effects
Used in clinical practice worldwide since FDA approval in 1996
Incorporated into guidelines for allergic rhinitis management by various allergy and immunology associations
Important role in improving quality of life in allergy sufferers

Side Or Adverse Effects

Headache is the most commonly reported side effect in both adults and children
Back pain observed occasionally in some patients
Mild cold symptoms such as nasal congestion, sinus discomfort, and sore throat reported
Rare reports of dizziness or dry mouth, particularly in overdose situations
Possible mild gastrointestinal discomfort including nausea or dyspepsia
Infrequent instances of fatigue or somnolence, though significantly less than first-generation antihistamines
Hypersensitivity reactions are rare but can include rash, hives, or angioedema
Serious allergic reactions (anaphylaxis, swelling of face or throat) require immediate medical attention
Flu-like symptoms such as fever, chills, or unusual tiredness have been reported and warrant physician consultation
Potential for worsening respiratory symptoms or cough—discuss with healthcare provider if these occur
Rare hepatic enzyme elevations noted in post-marketing surveillance but causal relationship uncertain
Overdose symptoms may include dry mouth, dizziness, and drowsiness
No evidence of QT interval prolongation or significant cardiac adverse effects at therapeutic doses
Generally well-tolerated; most side effects are transient and mild
Patients with pre-existing kidney disease may experience altered drug clearance leading to increased side effects

Precautions

Avoid using if allergic or hypersensitive to fexofenadine or any ingredient in the formulation
Use caution in patients with renal impairment; dosage adjustment may be necessary
Caution advised when administering to elderly patients due to potential increased sensitivity
Not recommended for use in children younger than 6 years for most formulations; follow age-specific instructions
Pregnant or breastfeeding women should consult healthcare providers before use due to limited safety data
Avoid concomitant use with fruit juices (apple, orange, grapefruit) due to reduced absorption and efficacy
Do not co-administer with antacids containing aluminum or magnesium within 2 hours as they decrease absorption
Use cautiously with other CNS depressants or sedatives as combined effects may be additive
Phenylketonuria patients should be cautious with formulations containing phenylalanine
Patients with a history of allergic reaction to antihistamines should be closely monitored
Avoid using for indication other than those approved or advised by a healthcare provider
Discontinue use and seek medical attention if signs of hypersensitivity or severe side effects develop
Use with caution in patients with pre-existing hepatic disease despite minimal metabolism
Inform healthcare providers of all medications being taken to assess for potential interactions
Ensure compliance with dosing instructions to minimize risk of adverse effects

Warnings

Do not take fexofenadine with fruit juices such as apple, orange, or grapefruit as they significantly reduce drug absorption and effectiveness
Avoid antacids containing magnesium or aluminum within 2 hours before or after dosing as they reduce bioavailability
Not recommended for children under 6 years of age for certain formulations; follow pediatric dosing guidance carefully
Seek immediate medical attention if signs of severe allergic reaction occur: hives, difficulty breathing, swelling of face, lips, tongue, or throat
Use caution in patients with kidney disease due to reduced elimination and increased risk of accumulation
Older adults may be more sensitive to the drug’s effects; monitor for adverse reactions
Pregnant or breastfeeding patients should consult healthcare providers for risk-benefit assessment
Overdose may cause dry mouth, dizziness, or drowsiness; emergency treatment should be sought immediately
Avoid using with other drugs that cause sedation unless advised by a physician, as additive CNS depression may occur
Avoid self-medicating or prolonged use without consultation if symptoms worsen or do not improve
Ensure medication is kept out of reach of children to prevent accidental ingestion
Do not share medication with others to prevent inappropriate use
Do not use disintegrating tablets in children younger than 6 years
Follow instructions precisely for use, especially regarding timing with food intake
Consult healthcare provider before use in patients with phenylketonuria due to phenylalanine content in some formulations

Contraindication

Known hypersensitivity or allergic reaction to fexofenadine or any of its components
Severe renal impairment without appropriate dose adjustment
Use of disintegrating tablets in children under 6 years of age
Concurrent intake of fruit juices just before or after dosing that cannot be avoided
Use in patients with phenylketonuria without medical supervision due to phenylalanine in product
Patients with history of allergic reactions to other antihistamines may require caution or contraindication
Severe hypersensitivity to other H1 receptor antagonists may warrant avoidance
Concomitant use with aluminum or magnesium-containing antacids without appropriate separation in timing
Caution or contraindication in pregnancy and breastfeeding unless benefits outweigh risk
Use with caution or avoid if concomitant drugs may result in drug interactions that impair elimination or increase toxicity
Contraindicated in situations where precise symptom control is critical and where non-sedating profile is essential but drug absorption would be impeded

Drug Interactions

Fruit juices (apple, orange, grapefruit) significantly reduce fexofenadine absorption via transporter inhibition
Antacids containing magnesium or aluminum reduce absorption if taken within 2 hours of fexofenadine
Ketoconazole and erythromycin may increase plasma levels of fexofenadine by inhibiting transporters
Co-administration with CNS depressants such as opioids, muscle relaxants, benzodiazepines may enhance sedation
No significant interaction with cytochrome P450 inducers or inhibitors due to minimal hepatic metabolism
Limited interaction potential with other antihistamines; concurrent use generally not recommended
No major interaction with oral contraceptives, though theoretical considerations remain
Magnesium and aluminum-containing antacids interfere with gastrointestinal absorption
Other over-the-counter cough, cold, or allergy medications may increase side effect profiles if combined
Potential for altered pharmacokinetics in patients taking drugs that affect renal excretion
No significant interaction with antihypertensives or most cardiac drugs documented
Concomitant use with herbal supplements like St. John's Wort not extensively studied; caution advised
Fexofenadine's elimination may be impacted by medications altering renal tubular secretion
No clinically relevant drug interactions reported with vitamins or mineral supplements
Healthcare providers should be informed of all concomitant medications to avoid potential unreported interactions

Preparations Of The Drug

Immediate-release oral tablets of fexofenadine hydrochloride in strengths including 30 mg, 60 mg, 120 mg, 180 mg, 220 mg, and 240 mg
Oral disintegrating tablets (ODT) designed for ease of administration without water, typically available in 30 mg and 60 mg doses
Oral suspension (liquid formulation) available for pediatric patients, concentrations such as 30 mg/5 mL or 30 mg/10 mL
Over-the-counter (OTC) formulations for allergy relief under brand names such as Allegra OTC and Aller-Ease
Prescription strength tablets including Allegra 12 Hour and Allegra 24 Hour Allergy formulations offering sustained release
Products formulated to avoid first-pass metabolism and maximize peripheral antihistaminic activity
Formulations free of sedative agents to minimize CNS effects
Liquid forms intended for pediatric dosing with provision of calibrated dosing cups or devices
Packaging designed to maintain stability at room temperature, protected from moisture and heat
Disintegrating tablets individually packaged in blister packs to preserve integrity until use
Phenylalanine content disclosed on some formulations due to presence in excipients, important for PKU patients
Available formulations do not contain significant preservatives that would limit use in sensitive populations
Manufactured under good manufacturing practices with consistent batch-to-batch potency
Various branded and generic preparations globally available with identical active ingredient
Product labeling includes recommendations for administration with water and avoidance with fruit juices